Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of antiplatelet thrombolysin in preparation of medicine for treating thrombotic thrombocytopenic purpura (TTP)

An anti-platelet and platelet technology, applied in the field of medicine, can solve problems such as clinical application limitations, and achieve the effect of preventing thrombocytopenia, inhibiting thrombocytopenia and cleavage hemolytic anemia, and inhibiting platelet aggregation

Pending Publication Date: 2016-08-10
ZHAOKE PHARMA HEFEI
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

70%-80% of TTP patients are acquired, so the clinical application of this approach is very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antiplatelet thrombolysin in preparation of medicine for treating thrombotic thrombocytopenic purpura (TTP)
  • Application of antiplatelet thrombolysin in preparation of medicine for treating thrombotic thrombocytopenic purpura (TTP)
  • Application of antiplatelet thrombolysin in preparation of medicine for treating thrombotic thrombocytopenic purpura (TTP)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Inhibitory Effect of Antiplatelet Thrombolytics on Platelet Aggregation Induced by Ristocin in Normal People and TTP Patients

[0023] 1. Sample collection

[0024] 3 cases of normal blood samples were collected from healthy blood workers. Three TTP patients were collected from emergency TTP patients, and all three patients had clinically typical "TTP triad", and their ADAMTS13 activity was lower than 10% in laboratory tests. The above samples were taken from peripheral venous blood, anticoagulated with trisodium citrate.

[0025] 2. Experimental method

[0026] (1) Platelet aggregation inhibition test (optical turbidimetry):

[0027] Whole blood was anticoagulated with 3.2% sodium citrate, centrifuged at 800prm for 10min to prepare PRP, and the remaining blood was centrifuged at 3000prm for 10min to prepare platelet-poor plasma (PPP). Adjust the platelet concentration of PRP to about 300×109 / L with PPP, adjust to zero with PPP, observe the change of light...

Embodiment 2

[0041] Example 2 Effectiveness Experiment of Antiplatelet Thrombolysin Used in Baboon Model of Acquired TTP

[0042] 1. Experimental Design and Methods

[0043] The experiment was divided into three groups with 4 animals in each group. The first group is the positive control. From the 0th day of the experiment, the dose of 600ug / kg anti-ADAMTS13 antibody 3H9 was injected every 48 hours through the femoral vein until the end of the 9th day of the experiment to establish the TTP model. Group 2 is the prevention group, injecting the same dose of 3H9 on the 1st and 3rd day, and subcutaneously injecting 0.3 mg / kg of anti-platelet thrombolysin on the 1st and 5th day, in order to observe its preventive effect on TTP. effect. The third group is the treatment group, starting from the 0th day of the experiment, injecting 600ug / kg of anti-ADAMTS13 antibody 3H9 every 48 hours through the femoral vein until the end of the 9th day of the experiment to establish the TTP model. Among them,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines and especially relates to an application of antiplatelet thrombolysin in preparation of a medicine for treating thrombotic thrombocytopenic purpura (TTP). The antiplatelet thrombolysin limits adhesion and aggregation of platelets, recovers levels of the platelets, erythrocytes and hemoglobin, reduces level of lactic dehydrogenase and effectively inhibits thrombocytopenia and cleaved-cell hemolyticanemia, thereby treating the TTP. The antiplatelet thrombolysin has great clinical application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of an anti-platelet thrombolysin in preparing a medicine for treating thrombotic thrombocytopenic purpura (Thrombotic Thrombocytopenic Purpura, TTP). Background technique [0002] Thrombotic Thrombocytopenic Purpura (TTP) is a severe disseminated thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, decreased consumption of platelet aggregation, and microthrombosis causing organ damage (such as the kidney, central nervous system, etc.) Its pathogenesis is closely related to a vWF protein cleavage enzyme (von Willebrand factor cleavage enzyme, ADAMTS13). The role of this enzyme is to specifically split the von Willebrand factor (vWF) in the blood to ensure the normal hemostasis of the human body. During the course of TTP, due to the decrease in the activity of this enzyme, vWF accumulates in large quantities on vascular endothelial cells and becom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61P7/04A61P7/02A61P7/06
CPCA61K38/48A61P7/02A61P7/06A61P7/04A61K38/4806
Inventor 李小羿戴向荣
Owner ZHAOKE PHARMA HEFEI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com